» Articles » PMID: 37624902

Early B-cell Development and B-cell Maturation Are Impaired in Patients with Active Hemophagocytic Lymphohistiocytosis

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is characterized by hyperinflammation and multiorgan dysfunction. Infections, including the reactivation of viruses, contribute to significant disease mortality in HLH. Although T-cell and natural killer cell-driven immune activation and dysregulation are well described, limited data exist on the status of B-cell compartment and humoral immune function in HLH. We noted marked suppression of early B-cell development in patients with active HLH. In vitro B-cell differentiation studies after exposure to HLH-defining cytokines, such as interferon gamma (IFN-γ) and tumor necrosis factor, recapitulated B-cell development arrest. Messenger RNA sequencing of human CD34+ cells exposed to IFN-γ demonstrated changes in genes and pathways affecting B-cell development and maturation. In addition, patients with active HLH exhibited a marked decrease in class-switched memory B (CSMB) cells and a decrease in bone marrow plasmablast/plasma cell compartments. The decrease in CSMB cells was associated with a decrease in circulating T follicular helper (cTfh) cells. Finally, lymph node and spleen evaluation in a patient with HLH revealed absent germinal center formation and hemophagocytosis with associated lymphopenia. Reassuringly, the frequency of CSMB and cTfh improved with the control of T-cell activation. Taken together, in patients with active HLH, these changes in B cells may affect the humoral immune response; however, further immune studies are needed to determine its clinical significance.

Citing Articles

Plasma Cell Neoplasms with Spreading in the Blood and Tissues: Extramedullary Myeloma Disease, a Rare Aggressive Form of Multiple Myeloma (First of Two Parts).

Testa U, Leone G Mediterr J Hematol Infect Dis. 2025; 17(1):e2025005.

PMID: 39830797 PMC: 11740910. DOI: 10.4084/MJHID.2025.005.


Patients and mice with deficiency in the SNARE protein SYNTAXIN-11 have a secondary B cell defect.

Kogl T, Chang H, Staniek J, Chiang S, Thoulass G, Lao J J Exp Med. 2024; 221(7).

PMID: 38722309 PMC: 11082451. DOI: 10.1084/jem.20221122.


Comprehensive evaluation of immune dysregulation in secondary hemophagocytic lymphohistiocytosis.

Wang Y, Yuan X, Wang T, Wei W, Wu S, Hou H Virulence. 2024; 15(1):2342276.

PMID: 38629410 PMC: 11028026. DOI: 10.1080/21505594.2024.2342276.

References
1.
Allende M, Tuymetova G, Lee B, Bonifacino E, Wu Y, Proia R . S1P1 receptor directs the release of immature B cells from bone marrow into blood. J Exp Med. 2010; 207(5):1113-24. PMC: 2867276. DOI: 10.1084/jem.20092210. View

2.
Das R, Guan P, Sprague L, Verbist K, Tedrick P, An Q . Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016; 127(13):1666-75. PMC: 4817310. DOI: 10.1182/blood-2015-12-684399. View

3.
Winslow G, Cooper A, Reiley W, Chatterjee M, Woodland D . Early T-cell responses in tuberculosis immunity. Immunol Rev. 2008; 225:284-99. PMC: 3827678. DOI: 10.1111/j.1600-065X.2008.00693.x. View

4.
Nguyen D, Joyner C, Sanz I, Lee F . Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells. Front Immunol. 2019; 10:2138. PMC: 6749102. DOI: 10.3389/fimmu.2019.02138. View

5.
Locatelli F, Jordan M, Allen C, Cesaro S, Rizzari C, Rao A . Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19):1811-1822. DOI: 10.1056/NEJMoa1911326. View